• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures.

作者信息

Caposiena Caro Raffaele Dante, Pensa Chiara, Lambiase Sara, Candi Eleonora, Bianchi Luca

机构信息

Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy.

Dermatology Department, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.

出版信息

Dermatol Ther. 2021 Nov;34(6):e15116. doi: 10.1111/dth.15116. Epub 2021 Sep 7.

DOI:10.1111/dth.15116
PMID:34459075
Abstract
摘要

相似文献

1
Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures.在抗TNF和抗白细胞介素-17治疗失败后，司库奇尤单抗对一例顽固性化脓性汗腺炎的疗效。
Dermatol Ther. 2021 Nov;34(6):e15116. doi: 10.1111/dth.15116. Epub 2021 Sep 7.
2
Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.司库奇尤单抗治疗化脓性汗腺炎的疗效和安全性：病例系列
Acta Derm Venereol. 2022 Sep 28;102:adv00780. doi: 10.2340/actadv.v102.2926.
3
Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.用阿达木单抗治疗重度顽固性化脓性汗腺炎。
J Dtsch Dermatol Ges. 2009 Feb;7(2):139-41. doi: 10.1111/j.1610-0387.2008.06918.x.
4
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha.抗肿瘤坏死因子α治疗失败后，使用司库奇尤单抗成功治疗顽固性化脓性汗腺炎。
Br J Dermatol. 2021 May;184(5):966-967. doi: 10.1111/bjd.19716. Epub 2021 Feb 1.
5
Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.使用白细胞介素-17A抗体司库奇尤单抗成功治疗重度顽固性化脓性汗腺炎
Acta Derm Venereol. 2018 Jan 12;98(1):151-152. doi: 10.2340/00015555-2794.
6
Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure.戈利木单抗用于治疗既往肿瘤坏死因子-α治疗失败的化脓性汗腺炎患者。
J Invest Dermatol. 2021 Dec;141(12):2975-2979. doi: 10.1016/j.jid.2021.04.026. Epub 2021 Jun 5.
7
Rotational therapy with TNF-alpha blockers for recalcitrant hidradenitis suppurativa.使用肿瘤坏死因子-α阻滞剂进行旋转疗法治疗顽固性化脓性汗腺炎。
Eur J Dermatol. 2010 Sep-Oct;20(5):644-6. doi: 10.1684/ejd.2010.1037. Epub 2010 Jul 9.
8
Hidradenitis suppurativa unresponsive to canakinumab treatment: A case report.
Indian J Dermatol Venereol Leprol. 2017 Sep-Oct;83(5):615-617. doi: 10.4103/ijdvl.IJDVL_147_16.
9
Psoriasis Onset during Anti-TNF Treatment for Hidradenitis Suppurativa: Successful Remission of Both Conditions with Secukinumab.化脓性汗腺炎抗TNF治疗期间银屑病发病：司库奇尤单抗成功缓解两种病症。
Skinmed. 2023 Mar 29;21(1):57-58. eCollection 2023.
10
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review.每4周使用100毫克古塞库单抗治疗化脓性汗腺炎患者及文献综述
Dermatol Ther. 2020 May;33(3):e13456. doi: 10.1111/dth.13456. Epub 2020 May 3.

引用本文的文献

1
European S2k guidelines for hidradenitis suppurativa/acne inversa part 2: Treatment.欧洲化脓性汗腺炎/反向性痤疮S2k指南第2部分：治疗
J Eur Acad Dermatol Venereol. 2025 May;39(5):899-941. doi: 10.1111/jdv.20472. Epub 2024 Dec 19.
2
CD2 expressing innate lymphoid and T cells are critical effectors of immunopathogenesis in hidradenitis suppurativa.表达 CD2 的固有淋巴细胞和 T 细胞是化脓性汗腺炎发病机制中的关键效应细胞。
Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2409274121. doi: 10.1073/pnas.2409274121. Epub 2024 Nov 19.
3
Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience.
银屑病中IL17和IL23抑制剂之间的跨类转换：一项真实生活、长期、单中心经验
J Clin Med. 2023 Dec 5;12(24):7503. doi: 10.3390/jcm12247503.
4
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
5
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.
6
New Insight into the Molecular Pathomechanism and Immunomodulatory Treatments of Hidradenitis Suppurativa.深入了解化脓性汗腺炎的分子发病机制和免疫调节治疗。
Int J Mol Sci. 2023 May 8;24(9):8428. doi: 10.3390/ijms24098428.
7
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.阿达木单抗治疗化脓性汗腺炎时出现矛盾性银屑病样反应：真实世界经验及对其他生物制剂的治疗反应。
Dermatol Ther. 2022 Dec;35(12):e15866. doi: 10.1111/dth.15866. Epub 2022 Oct 13.
8
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations.免疫调节药物治疗化脓性汗腺炎：可能性与局限性。
Int J Mol Sci. 2022 Aug 26;23(17):9716. doi: 10.3390/ijms23179716.
9
Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series.司库奇尤单抗治疗化脓性汗腺炎的疗效和安全性：病例系列
Acta Derm Venereol. 2022 Sep 28;102:adv00780. doi: 10.2340/actadv.v102.2926.
10
New and Emerging Targeted Therapies for Hidradenitis Suppurativa.化脓性汗腺炎的新型及新兴靶向治疗方法
Int J Mol Sci. 2022 Mar 29;23(7):3753. doi: 10.3390/ijms23073753.